Food allergy drug safety trial ends early
NCT ID NCT05678959
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at the long-term safety of ligelizumab, an injectable drug, in 163 people with food allergies who had already completed earlier Phase III studies. Participants received either 120 mg or 240 mg of ligelizumab every 4 weeks. The study was terminated, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ligelizumab (an injectable drug)
What this could lead to
If successful, this could show that ligelizumab is safe for long-term use and may help control food allergies.
What could go wrong
The study was terminated early, so results are limited. It is an extension study, not a new treatment test, and long-term safety is still uncertain.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOOD ALLERGY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Allergy and Asthma Associates of Santa Clara Vally Center
San Jose, California, 95117, United States
-
Allergy and Asthma Clin Res Inc
Walnut Creek, California, 94598, United States
-
Allergy and Immunology Associates
Scottsdale, Arizona, 85251, United States
-
Allervie Clinical Research
Birmingham, Alabama, 35209, United States
-
Ann and Robert H Lurie Childs Hosp
Chicago, Illinois, 60611, United States
-
Arkansas Children's Hospital
Little Rock, Arkansas, 72202, United States
-
Asthma and Allergy Associates P C
Colorado Springs, Colorado, 80907, United States
-
Atlanta Allergy and Asthma Clinic
Marietta, Georgia, 30062, United States
-
Boston Childrens Hospital
Boston, Massachusetts, 02215, United States
-
Childrens Healthcare of Atlanta
Atlanta, Georgia, 30342, United States
-
Childrens Hospital Of Philadelphia
Philadelphia, Pennsylvania, 19104, United States
-
Cincinnati Childrens Hospital MC
Cincinnati, Ohio, 45229-3039, United States
-
Family Allergy and Asthma
Lousiville, Kentucky, 40217, United States
-
Johns Hopkins Childrens Center
Baltimore, Maryland, 21287, United States
-
Mt Sinai Medical Center
New York, New York, 10029-6574, United States
-
Northwell Health
New York, New York, 10028, United States
-
Novartis Investigative Site
Brisbane, Queensland, 4101, Australia
-
Novartis Investigative Site
Parkville, Victoria, 3052, Australia
-
Novartis Investigative Site
Nedlands, Western Australia, 6009, Australia
-
Novartis Investigative Site
Hamilton, Ontario, L8N 3Z5, Canada
-
Novartis Investigative Site
Ottawa, Ontario, K1Y 4G2, Canada
-
Novartis Investigative Site
Toronto, Ontario, M3B 3S6, Canada
-
Novartis Investigative Site
Montreal, Quebec, H3T 1C5, Canada
-
Novartis Investigative Site
Québec, Quebec, G1V 4W2, Canada
-
Novartis Investigative Site
Angers, France, 49933, France
-
Novartis Investigative Site
Lille, 59000, France
-
Novartis Investigative Site
Toulouse, 31400, France
-
Novartis Investigative Site
Vandœuvre-lès-Nancy, 54511, France
-
Novartis Investigative Site
Frankfurt am Main, Hesse, 60590, Germany
-
Novartis Investigative Site
Frankfurt am Main, Hesse, 60596, Germany
-
Novartis Investigative Site
Dresden, Saxony, 01307, Germany
-
Novartis Investigative Site
Berlin, 13353, Germany
-
Novartis Investigative Site
Padova, PD, 35128, Italy
-
Novartis Investigative Site
Sagamihara, Kanagawa, 252-0392, Japan
-
Novartis Investigative Site
Setagaya-ku, Tokyo, 157-8535, Japan
-
Novartis Investigative Site
Utrecht, 3584 CX, Netherlands
-
Novartis Investigative Site
Esplugues, Barcelona, 08950, Spain
-
Novartis Investigative Site
Barcelona, 08036, Spain
-
Novartis Investigative Site
Madrid, 28009, Spain
-
Novartis Investigative Site
Madrid, 28040, Spain
-
Respiratory Medicine Research Institute of Michigan
Ypsilanti, Michigan, 48197, United States
-
Seattle Allergy and Asthma Rsch
Seattle, Washington, 98115, United States
-
Texas Childrens Hospital
Houston, Texas, 77030, United States
-
UBMD Pediatrics
Buffalo, New York, 14203, United States
-
UCHealth Outpatient Pavilion
Aurora, Colorado, 80045, United States
-
Univ of South Florida Asthma Allergy and Immunology CRU
Tampa, Florida, 33613, United States
-
University Of NC At Chapel Hill
Chapel Hill, North Carolina, 27599 9500, United States
-
University of Michigan Clinical Trials Office
Ann Arbor, Michigan, 48109, United States
-
Unv of TX Southwestern Medical Center
Dallas, Texas, 75235, United States